Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 82, Issue 4 , Pages 295-303 , April 2010

Polyunsaturated fatty acids, neuroinflammation and well being

References 

  1. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends in Neurosciences. 2000;23(12):618–625
  2. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Annual New York Academical Sciences. 2001;933:222–234
  3. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Review Neurosciences. 2008;9(1):46–56
  4. Kent S, Bluthe RM, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends in Pharmacological Sciences. 1992;13(1):24–28
  5. Venters HD, Dantzer R, Kelley KW. A new concept in neurodegeneration: TNFalpha is a silencer of survival signals. Trends in Neurosciences. 2000;23(4):175–180
  6. Allan SM. The role of pro- and antiinflammatory cytokines in neurodegeneration. Annual New York Academical Sciences. 2000;917:84–93
  7. Benito C, Tolon RM, Pazos MR, Nunez E, Castillo AI, Romero J. Cannabinoid CB2 receptors in human brain inflammation. British Journal of Pharmacology. 2008;153(2):277–285
  8. Lipton JM, Zhao H, Ichiyama T, Barsh GS. Catania A. Mechanisms of antiinflammatory action of alpha-MSH peptides. In vivo and in vitro evidence. Annual New York Academical Sciences. 1999;173–182
  9. Strle K, Zhou JH, Shen WH, Broussard SR, Johnson RW, Freund GG, et al. Interleukin-10 in the brain. Critical Review in Immunology. 2001;21(5):427–449
  10. Raper NR, Cronin FJ, Exler J. Omega-3 fatty acid content of the US food supply. Journal of American College of Nutrition. 1992;11(3):304–308
  11. Simopoulos AP. n-3 fatty acids and human health: defining strategies for public policy. Lipids. 2001;Suppl:S83–89:36
  12. Simopoulos AP. Importance of the ratio of omega-6/omega-3 essential fatty acids: evolutionary aspects. World Review in Nutritional Diet. 2003;92:1–22
  13. Calder PC. The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukotrienes Essential Fatty Acids. 2008;79(3–5):101–108
  14. Anderson GJ, Connor WE. Accretion of n-3 fatty acids in the brain and retina of chicks fed a low-linolenic acid diet supplemented with docosahexaenoic acid. American Journal of Clinical Nutrition. 1994;59(6):1338–1346
  15. Champeil-Potokar G, Denis I, Goustard-Langelier B, Alessandri JM, Guesnet P, Lavialle M. Astrocytes in culture require docosahexaenoic acid to restore the n-3/n-6 polyunsaturated fatty acid balance in their membrane phospholipids. Journal of Neuroscience Research. 2004;75(1):96–106
  16. Rosenberger TA, Villacreses NE, Hovda JT, Bosetti F, Weerasinghe G, Wine RN, et al. Rat brain arachidonic acid metabolism is increased by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide. Journal of Neurochemistry. 2004;88(5):1168–1178
  17. Rivest S. How circulating cytokines trigger the neural circuits that control the hypothalamic–pituitary–adrenal axis. Psychoneuroendocrinology. 2001;26(8):761–788
  18. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration?. Nature Review Neurosciences. 2002;3(3):216–227
  19. Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. Journal of Leukocyte Biology. 2004;75(3):388–397
  20. Kloss CU, Bohatschek M, Kreutzberg GW, Raivich G. Effect of lipopolysaccharide on the morphology and integrin immunoreactivity of ramified microglia in the mouse brain and in cell culture. Experimental Neurology. 2001;168(1):32–46
  21. Theele DP, Streit WJ. A chronicle of microglial ontogeny. Glia. 1993;7(1):5–8
  22. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annual Review of Immunology. 2009;27:119–145
  23. Nakamura Y. Regulating factors for microglial activation. Biological and Pharmacological Bulletin. 2002;25(8):945–953
  24. Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Progress in Neurobiology. 1999;57(6):563–581
  25. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunology. 2001;2(8):675–680
  26. Konsman JP, Kelley K, Dantzer R. Temporal and spatial relationships between lipopolysaccharide-induced expression of Fos, interleukin-1beta and inducible nitric oxide synthase in rat brain. Neuroscience. 1999;89(2):535–548
  27. Laflamme N, Rivest S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. Faseb Journal. 2001;15(1):155–163
  28. Laye S, Parnet P, Goujon E, Dantzer R. Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Molecular Brain Research. 1994;27(1):157–162
  29. Quan N, Sundar SK, Weiss JM. Induction of interleukin-1 in various brain regions after peripheral and central injections of lipopolysaccharide. Journal of Neuroimmunology. 1994;49(1–2):125–134
  30. Kluger MJ. Fever: role of pyrogens and cryogens. Physiological Reviews. 1991;71(1):93–127
  31. Laflamme N, Rivest S. Effects of systemic immunogenic insults and circulating proinflammatory cytokines on the transcription of the inhibitory factor kappaB alpha within specific cellular populations of the rat brain. Journal of Neurochemistry. 1999;73(1):309–321
  32. Chakravarty S, Herkenham M. Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. Journal of Neurosciences. 2005;25(7):1788–1796
  33. Laflamme N, Echchannaoui H, Landmann R, Rivest S. Cooperation between toll-like receptor 2 and 4 in the brain of mice challenged with cell wall components derived from gram-negative and gram-positive bacteria. European Journal of Immunology. 2003;33(4):1127–1138
  34. Kenny EF, O'Neill LA. Signalling adaptors used by Toll-like receptors: an update. Cytokine. 2008;43(3):342–349
  35. O'Neill LA, Fitzgerald KA, Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends in Immunology. 2003;24(6):286–290
  36. Laflamme N, Lacroix S, Rivest S. An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. Journal of Neurosciences. 1999;19(24):10923–10930
  37. Quan N, Whiteside M, Kim L, Herkenham M. Induction of inhibitory factor kappaBalpha mRNA in the central nervous system after peripheral lipopolysaccharide administration: an in situ hybridization histochemistry study in the rat. In: Proceedings of the National Academy of Sciences. 1997;94(20):10985–10990
  38. Eriksson C, Nobel S, Winblad B, Schultzberg M. Expression of interleukin 1 alpha and beta, and interleukin 1 receptor antagonist mRNA in the rat central nervous system after peripheral administration of lipopolysaccharides. Cytokine. 2000;12(5):423–431
  39. Nadjar A, Combe C, Laye S, Tridon V, Dantzer R, Amedee T, et al. Nuclear factor kappaB nuclear translocation as a crucial marker of brain response to interleukin-1. A study in rat and interleukin-1 type I deficient mouse. Journal of Neurochemistry. 2003;87(4):1024–1036
  40. Parnet P, Pousset F, Laye S. NF kappa B activation in mouse pituitary: comparison of response to interleukin-1 beta and lipopolysaccharide. Journal of Neuroendocrinology. 2003;15(3):304–314
  41. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunological Reviews. 2008;226(Dec):10–18
  42. Colotta F, Dower SK, Sims JE, Mantovani A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunology Today. 1994;15(12):562–566
  43. Cunningham ET, Wada E, Carter DB, Tracey DE, Battey JF, De Souza EB. Localization of interleukin-1 receptor messenger RNA in murine hippocampus. Endocrinology. 1991;128(5):2666–2668
  44. Ericsson A, Liu C, Hart RP, Sawchenko PE. Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. Journal of Comparitive Neurology. 1995;361(4):681–698
  45. Wong ML, Licinio J. Localization of interleukin 1 type I receptor mRNA in rat brain. Neuroimmunomodulation. 1994;1(2):110–115
  46. French RA, VanHoy RW, Chizzonite R, Zachary JF, Dantzer R, Parnet P, et al. Expression and localization of p80 and p68 interleukin-1 receptor proteins in the brain of adult mice. Journal of Neuroimmunology. 1999;93(1–2):194–202
  47. Ilyin SE, Gayle D, Flynn MC, Plata-Salaman CR. Interleukin-1beta system (ligand, receptor type I, receptor accessory protein and receptor antagonist), TNF-alpha, TGF-beta1 and neuropeptide Y mRNAs in specific brain regions during bacterial LPS-induced anorexia. Brain Research Bulletin. 1998;45(5):507–515
  48. Liu C, Chalmers D, Maki R, De Souza EB. Rat homolog of mouse interleukin-1 receptor accessory protein: cloning, localization and modulation studies. Journal of Neuroimmunology. 1996;66(1–2):41–48
  49. Smith DE, Lipsky BP, Russell C, Ketchem RR, Kirchner J, Hensley K, et al. A central nervous system-restricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin-1. Immunity. 2009;30(6):817–831
  50. Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA, Massa PT. Induction of IL-33 expression and activity in central nervous system glia. Journal of Leukocyte Biology. 2008;84(3):631–643
  51. Pinteaux E, Parker LC, Rothwell NJ, Luheshi GN. Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. Journal of Neurochemistry. 2002;83(4):754–763
  52. Costelloe C, Watson M, Murphy A, McQuillan K, Loscher C, Armstrong ME, et al. IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8. Journal of Neurochemistry. 2008;105(5):1960–1969
  53. Hart BL. Biological basis of the behavior of sick animals. Neuroscience and Biobehavioral Reviews. 1988;12(2):123–137
  54. Laye S, Bluthe RM, Kent S, Combe C, Medina C, Parnet P, et al. Subdiaphragmatic vagotomy blocks induction of IL-1 beta mRNA in mice brain in response to peripheral LPS. American Journal of Physiology. 1995;268(5 Pt 2):R1327–R1331
  55. Laye S, Gheusi G, Cremona S, Combe C, Kelley K, Dantzer R, et al. Endogenous brain IL-1 mediates LPS-induced anorexia and hypothalamic cytokine expression. American Journal of Physiology. 2000;279(1):R93–R98
  56. Kent S, Bluthe RM, Dantzer R, Hardwick AJ, Kelley KW, Rothwell NJ, et al. Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. In: Proceedings of the National Academy of Sciences. 1992;89(19):9117–9120
  57. Cremona S, Goujon E, Kelley KW, Dantzer R, Parnet P. Brain type I but not type II IL-1 receptors mediate the effects of IL-1 beta on behavior in mice. American Journal of Physiology. 1998;274(3 Pt 2):R735–R740
  58. Cremona S, Laye S, Dantzer R, Parnet P. Blockade of brain type II interleukin-1 receptors potentiates IL1beta-induced anorexia in mice. Neuroscience Letters. 1998;246(2):101–104
  59. Bluthe RM, Laye S, Michaud B, Combe C, Dantzer R, Parnet P. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. European Journal of Neurosciences. 2000;12(12):4447–4456
  60. Laye S, Liege S, Li KS, Moze E, Neveu PJ. Physiological significance of the interleukin 1 receptor accessory protein. Neuroimmunomodulation. 2001;9(4):225–230
  61. Liege S, Laye S, Li KS, Moze E, Neveu PJ. Interleukin 1 receptor accessory protein (IL-1RAcP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1beta. Journal of Neuroimmunology. 2000;110(1-2):134–139
  62. Touzani O, Boutin H, LeFeuvre R, Parker L, Miller A, Luheshi G, et al. Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. Journal of Neurosciences. 2002;22(1):38–43
  63. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282(5396):2085–2088
  64. Johnson RW, Gheusi G, Segreti S, Dantzer R, Kelley KW. C3H/HeJ mice are refractory to lipopolysaccharide in the brain. Brain Research. 1997;752(1-2):219–226
  65. Segreti J, Gheusi G, Dantzer R, Kelley KW, Johnson RW. Defect in interleukin-1beta secretion prevents sickness behavior in C3H/HeJ mice. Physiology of Behavior. 1997;61(6):873–878
  66. Dvoriantchikova G, Barakat D, Brambilla R, Agudelo C, Hernandez E, Bethea JR, et al. Inactivation of astroglial NF-kappaB promotes survival of retinal neurons following ischemic injury. European Journal of Neurosciences. 2009;30(2):175–185
  67. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behavior and Immunity. 2003;17(Suppl 1):S119–S124
  68. Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919–2925
  69. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, et al. Neuroinflammation in Alzheimer’s disease and prion disease. Glia. 2002;40(2):232–239
  70. Gidron Y, Gilutz H, Berger R, Huleihel M. Molecular and cellular interface between behavior and acute coronary syndromes. Cardiovascular Research. 2002;56(1):15–21
  71. Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. Journal of Psychosomatic Research. 2002;53(4):873–876
  72. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. Journal of Pharmacology and Experimental Therapy. 2003;304(1):1–7
  73. Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: helpful and harmful. Trends in Neurosciences. 1996;19(8):331–338
  74. Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke. 1994;25(4):869–875discussion 875‐866
  75. Dusart I, Schwab ME. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. European Journal of Neurosciences. 1994;6(5):712–724
  76. Gendelman HE, Zheng J, Coulter CL, Ghorpade A, Che M, Thylin M, et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. Journal of Infectious Disease. 1998;178(4):1000–1007
  77. Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G, et al. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurology. 2002;1(8):499–509
  78. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease. Neurology. 1992;42(2):447–449
  79. Aschner M. Astrocytes as mediators of immune and inflammatory responses in the CNS. Neurotoxicology. 1998;19(2):269–281
  80. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends in Neurosciences. 1996;19(8):312–318
  81. Kielian T, Esen N. Effects of neuroinflammation on glia–glia gap junctional intercellular communication: a perspective. Neurochemistry International. 2004;45(2-3):429–436
  82. Nakase T, Fushiki S, Sohl G, Theis M, Willecke K, Naus CC. Neuroprotective role of astrocytic gap junctions in ischemic stroke. Cell Communication and Adhesion. 2003;10(4–6):413–417
  83. Griffin DE, Moser HW, Mendoza Q, Moench TR, O'Toole S, Moser AB. Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Annals of Neurology. 1985;18(6):660–664
  84. Hetier E, Ayala J, Denefle P, Bousseau A, Rouget P, Mallat M, et al. Brain macrophages synthesize interleukin-1 and interleukin-1 mRNAs in vitro. Journal of Neuroscience Research. 1988;21(2–4):391–397
  85. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 1990;40(11):1735–1739
  86. Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. Journal of Neuropathology and Experimental Neurology. 1995;54(2):276–281
  87. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. In: Proceedings of the National Academy of Sciences. 1989;86(19):7611–7615
  88. Katafuchi T, Takaki A, Take S, Kondo T, Yoshimura M. Endotoxin inhibitor blocks heat exposure-induced expression of brain cytokine mRNA in aged rats. Molecular Brain Research. 2003;118(1–2):24–32
  89. Hacham M, Argov S, White RM, Segal S, Apte RN. Different patterns of interleukin-1alpha and interleukin-1beta expression in organs of normal young and old mice. European Cytokine Network. 2002;13(1):55–65
  90. Lynch MA. Age-related impairment in long-term potentiation in hippocampus: a role for the cytokine, interleukin-1 beta?. Progress in Neurobiology. 1998;56(5):571–589
  91. Kanemoto K, Kawasaki J, Miyamoto T, Obayashi H, Nishimura M. Interleukin (IL)1beta, IL-1alpha, and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy. Annals of Neurology. 2000;47(5):571–574
  92. Mrak RE, Griffin WS. Interleukin-1 and the immunogenetics of Alzheimer disease. Journal of Neuropathology and Experimental Neurology. 2000;59(6):471–476
  93. Nishimura M, Mizuta I, Mizuta E, Yamasaki S, Ohta M, Kuno S. Influence of interleukin-1beta gene polymorphisms on age-at-onset of sporadic Parkinson's disease. Neuroscience Letters. 2000;284(1–2):73–76
  94. Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C, et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Molecular Psychiatry. 2009;Feb:10
  95. Sheng JG, Griffin WS, Royston MC, Mrak RE. Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer’s disease. Neuropathology and Applied Neurobiology. 1998;24(4):278–283
  96. Sly LM, Krzesicki RF, Brashler JR, Buhl AE, McKinley DD, Carter DB, et al. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer’s disease. Brain Research Bulletin. 2001;56(6):581–588
  97. McLay RN, Kastin AJ, Zadina JE. Passage of interleukin-1-beta across the blood–brain barrier is reduced in aged mice: a possible mechanism for diminished fever in aging. Neuroimmunomodulation. 2000;8(3):148–153
  98. Plata-Salaman CR, Peloso E, Satinoff E. Interleukin-1beta-induced fever in young and old Long-Evans rats. American Journal of Physiology. 1998;275(5 Pt 2):R1633–R1638
  99. Lynch AM, Lynch MA. The age-related increase in IL-1 type I receptor in rat hippocampus is coupled with an increase in caspase-3 activation. European Journal of Neurosciences. 2002;15(11):1779–1788
  100. Murray CA, Lynch MA. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. Journal of Neurosciences. 1998;18(8):2974–2981
  101. Campbell VA, Segurado R, Lynch MA. Regulation of intracellular Ca2+ concentration by interleukin-1beta in rat cortical synaptosomes: an age-related study. Neurobiology of Aging. 1998;19(6):575–579
  102. Goshen I, Kreisel T, Ounallah-Saad H, Renbaum P, Zalzstein Y, Ben-Hur T, et al. A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology. 2007;32(8-10):1106–1115
  103. Labrousse VF, Costes L, Aubert A, Darnaudery M, Ferreira G, Amedee T, et al. Impaired interleukin-1beta and c-Fos expression in the hippocampus is associated with a spatial memory deficit in P2X(7) receptor-deficient mice. PloS One. 2009;4(6):e6006
  104. Bourre JM, Dumont O, Piciotti M, Clement M, Chaudiere J, Bonneil M, et al. Essentiality of omega 3 fatty acids for brain structure and function. World Review in Nutritional Diet. 1991;66:103–117
  105. O'Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Critical Review in Neurobiology. 1999;13(1):45–82
  106. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37–40
  107. Kozak KR, Prusakiewicz JJ, Rowlinson SW, Schneider C, Marnett LJ. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. Journal of Biological Chemistry. 2001;276(32):30072–30077
  108. Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids. 2003;38(4):343–352
  109. Calder PC, Grimble RF. Polyunsaturated fatty acids, inflammation and immunity. European Journal of Clinical Nutrition. 2002;56(Suppl 3):S14–S19
  110. Zaloga GP, Marik P. Lipid modulation and systemic inflammation. Critical Care Clinical. 2001;17(1):201–217
  111. Petroni A, Salami M, Blasevich M, Papini N, Galli C. Inhibition by n-3 fatty acids of arachidonic acid metabolism in a primary culture of astroglial cells. Neurochemistry Research. 1994;19(9):1187–1193
  112. Mingam R, Moranis A, Bluthe RM, De Smedt-Peyrusse V, Kelley KW, Guesnet P, et al. Uncoupling of interleukin-6 from its signalling pathway by dietary n-3-polyunsaturated fatty acid deprivation alters sickness behaviour in mice. European Journal of Neurosciences. 2008;28(9):1877–1886
  113. De Smedt-Peyrusse V, Sargueil F, Moranis A, Harizi H, Mongrand S, Laye S. Docosahexaenoic acid prevents lipopolysaccharide-induced cytokine production in microglial cells by inhibiting lipopolysaccharide receptor presentation but not its membrane subdomain localization. Journal of Neurochemistry. 2008;105(2):296–307
  114. Bazan NG. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer’s disease. Journal of Lipid Research. 2009;Suppl:S400–405:50
  115. Bazan NG, Marcheselli VL, Cole-Edwards K. Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Annual New York Academical Sciences. 2005;1053(Aug):137–147
  116. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nature Medicine. 2007;13(7):868–873
  117. Serhan CN, Clish CB, Brannon J, Colgan SP, Gronert K, Chiang N. Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. Journal of Physiology and Pharmacology. 2000;51(4 Pt 1):643–654
  118. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. Journal of Biological Chemistry. 2003;278(44):43807–43817
  119. Cooper AL, Rothwell NJ. Inhibition of the thermogenic and pyrogenic responses to interleukin-1 beta in the rat by dietary N-3 fatty acid supplementation. Prostaglandins Leukotrienes Essential Fatty Acids. 1993;49(2):615–626
  120. Pomposelli JJ, Mascioli EA, Bistrian BR, Lopes SM, Blackburn GL. Attenuation of the febrile response in guinea pigs by fish oil enriched diets. Journal of Parenteral and Enteral Nutrition. 1989;13(2):136–140
  121. Kozak W, Soszynski D, Rudolph K, Conn CA, Kluger MJ. Dietary n-3 fatty acids differentially affect sickness behavior in mice during local and systemic inflammation. American Journal of Physiology. 1997;272(4 Pt 2):R1298–R1307
  122. Kunkel SL, Spengler M, May MA, Spengler R, Larrick J, Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. Journal of Biological Chemistry. 1988;263(11):5380–5384
  123. Klir JJ, McClellan JL, Kozak W, Szelenyi Z, Wong GH, Kluger MJ. Systemic but not central administration of tumor necrosis factor-alpha attenuates LPS-induced fever in rats. American Journal of Physiology. 1995;268(2 Pt 2):R480–R486
  124. Kozak W, Conn CA, Klir JJ, Wong GH, Kluger MJ. TNF soluble receptor and antiserum against TNF enhance lipopolysaccharide fever in mice. American Journal of Physiology. 1995;269(1 Pt 2):R23–R29
  125. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Fish Renaud S. Meat, and risk of dementia: cohort study. British Medical Journal. 2002;325(7370):932–933
  126. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Annals of Neurology. 1997;42(5):776–782
  127. Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology. 2004;62(2):275–280
  128. McGahon B, Murray CA, Clements MP, Lynch MA. Analysis of the effect of membrane arachidonic acid concentration on modulation of glutamate release by interleukin-1: an age-related study. Experimental Gerontology. 1998;33(4):343–354
  129. Babcock T, Helton WS, Espat NJ. Eicosapentaenoic acid (EPA): an antiinflammatory omega-3 fat with potential clinical applications. Nutrition. 2000;16(11–12):1116–1118
  130. Martin DS, Lonergan PE, Boland B, Fogarty MP, Brady M, Horrobin DF, et al. Apoptotic changes in the aged brain are triggered by interleukin-1beta-induced activation of p38 and reversed by treatment with eicosapentaenoic acid. Journal of Biological Chemistry. 2002;277(37):34239–34246
  131. Kelly A, Vereker E, Nolan Y, Brady M, Barry C, Loscher CE, et al. Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus. Journal of Biological Chemistry. 2003;278(21):19453–19462
  132. Nadjar A, Bluthe RM, May MJ, Dantzer R, Parnet P. Inactivation of the cerebral NFkappaB pathway inhibits interleukin-1beta-induced sickness behavior and c-Fos expression in various brain nuclei. Neuropsychopharmacology. 2005;30(8):1492–1499
  133. Bluthe RM, Castanon N, Pousset F, Bristow A, Ball C, Lestage J, et al. Central injection of IL-10 antagonizes the behavioural effects of lipopolysaccharide in rats. Psychoneuroendocrinology. 1999;24(3):301–311
  134. Lynch AM, Moore M, Craig S, Lonergan PE, Martin DS, Lynch MA. Analysis of interleukin-1 beta-induced cell signaling activation in rat hippocampus following exposure to gamma irradiation. Protective effect of eicosapentaenoic acid. Journal of Biological Chemistry. 2003;278(51):51075–51084
  135. Song C, Zhang XY, Manku M. Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. Journal of Neurosciences. 2009;29(1):14–22
  136. Kavanagh T, Lonergan PE, Lynch MA. Eicosapentaenoic acid and gamma-linolenic acid increase hippocampal concentrations of IL-4 and IL-10 and abrogate lipopolysaccharide-induced inhibition of long-term potentiation. Prostaglandins Leukotrienes Essential Fatty Acids. 2004;70(4):391–397
  137. Song C, Horrobin D. Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory impairment induced by central IL-1beta administration. Journal of Lipid Research. 2004;45(6):1112–1121
  138. Song C, Li X, Leonard BE, Horrobin DF. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. Journal of Lipid Research. 2003;44(10):1984–1991

PII: S0952-3278(10)00050-5

doi: 10.1016/j.plefa.2010.02.006

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 82, Issue 4 , Pages 295-303 , April 2010

Article Tools

* Image Usage & Resolution